Acute Myeloid Leukemia Patients' Clinical Response to Idasanutlin (RG7388) Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts

Authors

Bernhard Reis
Lori Jukofsky
Gong Chen
Giovanni MartinelliFollow
Karen Seiter, New York Medical CollegeFollow
William Pierceall

First Page

185

Last Page

188

Document Type

Letter to the Editor

Publication Date

5-1-2016

Department

Medicine

Comments

Please see the work itself for the complete list of authors.

Recommended Citation

Reis, B., Jukofsky, L., Chen, G., Martinelli, G., Zhong, H., So, W. V., . . . Pierceall, W. E. (2016). Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. Haematologica, 101(5), e185-e188. doi:10.3324/haematol.2015.139717

Publisher's Statement

Originally published in Haematologica. Licensed under CC-BY 4.0. https://doi.org/10.3324/haematol.2015.139717